DrReddy’s Laboratories Ltd ADR is a drug manufacturers - specialty & generic business based in the US. DrReddy’s Laboratories Ltd ADR shares (RDY) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $79.20 – an increase of 2.51% over the previous week. DrReddy’s Laboratories Ltd ADR employs 27,048 staff and has a trailing 12-month revenue of around $288.5 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $79.20 |
|---|---|
| 52-week range | $62.97 - $84.46 |
| 50-day moving average | $80.58 |
| 200-day moving average | $75.26 |
| Wall St. target price | $85.62 |
| PE ratio | 19.9194 |
| Dividend yield | $40 (0.6%) |
| Earnings per share (TTM) | $3.97 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $79.08 from 2024-10-15
| 1 week (2024-10-10) | 2.36% |
|---|---|
| 1 month (2024-09-17) | -0.57% |
| 3 months (2024-07-17) | 0.48% |
| 6 months (2024-04-17) | 10.90% |
| 1 year (2023-10-17) | 19.24% |
|---|---|
| 2 years (2022-10-17) | 49.80% |
| 3 years (2021-10-15) | 19.80% |
| 5 years (2019-10-17) | 112.06% |
Valuing DrReddy’s Laboratories Ltd ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DrReddy’s Laboratories Ltd ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DrReddy’s Laboratories Ltd ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, DrReddy’s Laboratories Ltd ADR shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
DrReddy’s Laboratories Ltd ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.5506. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DrReddy’s Laboratories Ltd ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DrReddy’s Laboratories Ltd ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $79.5 billion.
The EBITDA is a measure of a DrReddy’s Laboratories Ltd ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $288.5 billion |
|---|---|
| Operating margin TTM | 23.39% |
| Gross profit TTM | $113.8 billion |
| Return on assets TTM | 10.93% |
| Return on equity TTM | 20.59% |
| Profit margin | 19.26% |
| Book value | $1,769.05 |
| Market Capitalization | $13.2 billion |
TTM: trailing 12 months
Dividend payout ratio: 0.29% of net profits
Recently DrReddy’s Laboratories Ltd ADR has paid out, on average, around 0.29% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.6% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), DrReddy’s Laboratories Ltd ADR shareholders could enjoy a 0.6% return on their shares, in the form of dividend payments. In DrReddy’s Laboratories Ltd ADR's case, that would currently equate to about $40 per share.
While DrReddy’s Laboratories Ltd ADR's payout ratio might seem low, this can signify that DrReddy’s Laboratories Ltd ADR is investing more in its future growth.
DrReddy’s Laboratories Ltd ADR's most recent dividend payout was on 11 August 2024. The latest dividend was paid out to all shareholders who bought their shares by 29 July 2024 (the "ex-dividend date").
DrReddy’s Laboratories Ltd ADR's shares were split on a 2:1 basis on 6 September 2006. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DrReddy’s Laboratories Ltd ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DrReddy’s Laboratories Ltd ADR shares which in turn could have impacted DrReddy’s Laboratories Ltd ADR's share price.
Over the last 12 months, DrReddy’s Laboratories Ltd ADR's shares have ranged in value from as little as $62.9687 up to $84.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DrReddy’s Laboratories Ltd ADR's is 0.312. This would suggest that DrReddy’s Laboratories Ltd ADR's shares are less volatile than average (for this exchange).
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.